Search company, investor...
PharmAthene company logo


Founded Year



Series C | Alive

Total Raised


Last Raised

$11.2M | 18 yrs ago



About PharmAthene

PharmAthene's primary objective is the development of effective countermeasures to a range of biological and chemical threats having potential lethal effects for the military or civilian populations. The Company is developing Valortim, an anthrax monoclonal antibody, in collaboration with Medarex, Inc. for pre- and post exposure prophylaxis and treatment, as well as Protexia, a recombinant human butyrylcholinesterase for treatment following exposure to chemical nerve agents.

Headquarters Location

One Park Place Suite 450

Annapolis, Maryland, 21401,

United States


Missing: PharmAthene's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: PharmAthene's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing PharmAthene

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PharmAthene is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

PharmAthene Patents

PharmAthene has filed 3 patents.

patents chart

Application Date

Grant Date


Related Topics




Vaccines, Vaccination, Biological warfare, Immunology, Influenza


Application Date


Grant Date



Related Topics

Vaccines, Vaccination, Biological warfare, Immunology, Influenza



Latest PharmAthene News

Adiponitrile Market Analysis by Top Players, Share and Forecast Upto 2025 | PharmAthene, Inc., Cleveland BioLabs, Ichor Medical Systems, Achaogen, Inc.

Aug 17, 2020

| PharmAthene, Inc., Cleveland BioLabs, Ichor Medical Systems, Achaogen, Inc. Pune, Maharashtra, India, August 17 2020 (Wiredrelease) Brandessence Market Research and Consulting Pvt ltd –: Adiponitrile Market delivers a succinct analysis of industry size, regional growth and revenue forecasts for the upcoming years. The report further sheds light on significant challenges and the latest growth strategies adopted by manufacturers who are a part of the competitive spectrum of this business domain. Global Adiponitrile Market is valued at USD 8.02 Billion in 2018 and expected to reach USD 11.21 Billion by 2025 with the CAGR of 4.9% over the forecast period. The increasing usage of Adiponitrile in Nylon-66 production and growing demand in the plastics and automotive industry are some of the major factors which are expected to drive the growth of Adiponitrile market. *The sample pages of this report is immediately accessible on-demand. ** Adiponitrile is a chemical used primarily in the manufacture of Hexamethylene Diamine (HMDA), which is used widely to prepare nylon. HMDA chemical is an important intermediate for the manufacture of synthetic fiber. Adiponitrile is used exclusively to make Hexamethylene Diamine (HMDA), of which 92% is used to make nylon 6, 6 fibers and resins. Adiponitrile is gaining importance as an electrolyte additive in lithium ion batteries which results in increased efficiency and overall performance of each battery cycle. Growing production of electric vehicles operating on Li-ion batteries is anticipated to fuel the demand for adiponitrile over the forecast period. Global Adiponitrile market report is segmented on the basis of type, application and regional & country level. Based upon type Adiponitrile market is classified into Industrial Grade and Non-Industrial Grade. Based upon application Adiponitrile market is classified into Carpet fibers, Conveyor belts, Electro-insulating elements and Plastic. The regions covered in this Global Adiponitrile market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level market of Adiponitrile is sub divided into U.S., Mexico, Canada, UK, France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc. Adiponitrile Market Vendors The Dow Chemical Company Invista   The increasing usage of Adiponitrile in Nylon-66 production and growing demand in the plastics and automotive industry are some of the major factors which are expected to drive the growth of Adiponitrile market. The increasing usage of Adiponitrile in Nylon-66 production and growing demand in the plastics and automotive industry are some of the major factors which are expected to drive the growth of Adiponitrile market. The demand for Nylon 66 is on the rise because of its high mechanical strength, rigidity, heat and chemical resistance, which makes it suitable for application in industries like Automotive, Plastics, Electronics, and Textile. There is significant growth in production of adiponitrile. For Example, Chemical and engineering news stated that Ascend a chemical manufacturer is expanding production capacity by 10–15% across the board for adiponitrile, HMD, adipic acid, and nylon 6, 6. In May, amid growing market worry, the Invista Company announced it had expanded adiponitrile capacity by 50,000 metric tons in 2017, is adding 40,000 metric tons by the end of this year, and will expand by another 180,000 metric tons by 2022. Use of Nylon 66 in automotive components has grown considerably for multiple new applications such as powertrains, electrical components, chassis, trim components, and other vehicle areas. The high-temperature resistance of Nylon 66 has also led to its applications in the engines. Polyamide 6, 6 resins is used in the manufacturing of exterior and interior automotive components to reduce weight of the vehicle and optimize fuel efficiency. According to Crafttech industries inc., there are top 13 high performance plastics used in automotive hardware. While all of this may be easily used in a single vehicle, just three types of plastic make up approximately 66% of the total high performance plastics used in a car like polypropylene (32%), polyurethane (17%) and PVC (16%). However, stringent governmental regulations due to environmental concerns related to the use of adiponitrile and fluctuating raw material prices are factors expected to restrict the growth of the global market. Increasing adoption of the adiponitrile and innovations or tech advancements in the field are some of factors can provide an opportunity for the growth of Adiponitrile market. North America is dominating the Adiponitrile Market North America is expected to dominate the growth of Adiponitrile Market, due to increasing demand of the Nylon 66, especially in the automotive and plastics sector. According to international trade administration, the United States has one of the largest automotive markets in the world. In 2018, U.S. light vehicle sales reached 17.2 million units, the fourth straight year in which sales reached or surpassed 17 million units. Overall, the United States is the world’s second-largest market for vehicle sales and production. Asia Pacific has witnessed increasing consumption of adiponitrile in automotive parts manufacturing owing to presence of numerous original equipment manufacturer across the region. Europe is expected to drive the growth of Adiponitrile Market, due to increasing adoption of the Adiponitrile in the formulation of battery electrolyte. Key Benefits for Global Adiponitrile Market Reports – Global market report covers in depth historical and forecast analysis. Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level. Global market report helps to identify opportunities in market place. Global market report covers extensive analysis of emerging trends and competitive landscape. Global Adiponitrile market Segmentation – By Application: Carpet fibers, Conveyor belts, Electro-insulating elements, Plastic Regional & Country Analysis North America, U.S., Mexico, Canada , Europe, UK, France, Germany, Italy , Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa Table of Content About Us: Brandessence Market Research and Consulting Pvt. ltd. Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London. Contact us at: +44-2038074155 or mail us at

PharmAthene Frequently Asked Questions (FAQ)

  • When was PharmAthene founded?

    PharmAthene was founded in 2001.

  • Where is PharmAthene's headquarters?

    PharmAthene's headquarters is located at One Park Place, Annapolis.

  • What is PharmAthene's latest funding round?

    PharmAthene's latest funding round is Series C.

  • How much did PharmAthene raise?

    PharmAthene raised a total of $61.2M.

  • Who are the investors of PharmAthene?

    Investors of PharmAthene include MPM Capital, Bear Stearns, Lumira Ventures, Teachers Private Capital and Chesapeake Innovation Center.

  • Who are PharmAthene's competitors?

    Competitors of PharmAthene include Humanetics, Symphogen, Altor BioScience, Merus, Theraclone Sciences and 12 more.

Compare PharmAthene to Competitors

Y's Therapeutics

Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs. The company also have small molecule compounds in the company's R&D pipeline to diversify the company's portfolio.


ModiQuest (CRO) focus is on generation of recombinant monoclonal antibodies (animal, human). The company use antigen specific B-cell selection combined with efficient hybridoma generation or direct antibody cDNA cloning from selected B-cells. MQR offers custom phage display services.


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.


MacuSight is a privately-held pharmaceutical company focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye. As part of its unique product development philosophy, MacuSight also concentrates on the optimal delivery of these compounds into the eye. By combining its compounds with innovative delivery approaches, the company strives to optimize the efficacy, safety, convenience and cost-effectiveness of its product candidates.

ImmunoReagents Logo

ImmunoReagents is a cGMP manufacturing facility for antibodies used in the In Vitro Diagnostic Industry, which specializes in polyclonal antibodies to human proteins and secondary antibodies.

Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.